Poster Abstract Session:
227. Clinical Trials
Saturday, October 6, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Investigative ID, Pediatric ID


Presentations:
Influenza Vaccination via Oral Tablet is Protective and Induces a Unique Mucosal Immune Response
Nikita Kolhatkar, PhD; Keith Gottlieb, PhD; Kassandra Kasparek, BS; Katie Hodgson, BS; Sean Tucker, PhD; David Liebowitz, M.D., PhD
A Host-response Assay Distinguishes Between Simple Influenza Patients and Influenza Patients with Bacterial Coinfection
Meital Paz, BSc; Kfir Oved, PhD; Tanya Gottlieb, PhD; Asi Cohen, PhD; Roy Navon, MSc; Niv Mastboim, BSc; Ellen Bamberger, MD; Tom Friedman, MD; Liat Etshtein, MD; Olga Boico, PhD; Isaac Srugo, MD; Irina Chistyakov, MD; Adi Klein, MD; Israel Potasman, MD, FIDSA; Eran Eden, PhD; Liran Shani, MD
Safety and Efficacy of Ambulatory Outpatient Treatment of Febrile Neutropenia in Children with Cancer in Mexico: A Multicenter Randomized Controlled Trial
Martha Avilés, MD, MSc; Marta Zapata, MD, MSc; Rómulo Rosales, MD; Francisco Otero, MD; Amilcar Valencia, MD; Jose Peñaloza, MD; Alfonso Reyes-Lopez, MsSc
Prevention of Recurrent Clostridium difficile at Six Months following Treatment with Microbiota-based Therapy RBX2660: Durability Results from a Phase 2 Open-Label Study
Sarah Mische, PhD; Robert Orenstein, DO, FIDSA; Erik R. Dubberke, MD, MSPH, FIDSA, FSHEA; Sahil Khanna, MBBS, MS; Gail Hecht, MD; Herbert Dupont, MD, FIDSA; Christine Lee, MD, FRCPC; Ken Blount, PhD
Nephrotoxicity associated with imipenem/cilastatin/relebactam (IMI/REL) versus imipenem/cilastatin plus colistin (IMI+CST) in patients with imipenem-nonsusceptible (NS) bacterial infections
Michelle Brown, RN; Johann Motsch, MD; Keith Kaye, MD, MPH; Thomas File, MD; Helen W. Boucher, MD, FIDSA; Neika Vendetti, MPH; Angela Aggrey, PhD; Hee-Koung Joeng, PhD; Robert Tipping, MS; Jiejun Du, PhD; Daryl D. Depestel, PharmD, BCPS-ID; Joan Butterton, MD; Nicholas A. Kartsonis, MD; Amanda Paschke, MD, MSCE
Evaluation of Relapse and Reinfection Using Whole-Genome Sequencing of Clostridium difficile Isolates from Elderly Patients with C. difficile Infection (CDI) in the EXTEND Randomised, Controlled, Comparative Study of Extended-Pulsed Fidaxomicin and Vancomycin for the Treatment of CDI
Mark Wilcox, MD; Oliver A. Cornely, MD; Benoit Guery, MD; Chris Longshaw, PhD; Areti Georgopali, MD; Andreas Karas, MD; Gbenga Kazeem, PhD; Jose Alejandro Palacios-Fabrega, PhD; Maria J. G. T. Vehreschild, MD
Comparative Effectiveness Of High- Versus Standard-dose Influenza Vaccine On Hospitalization For Acute Myocardial Infarction In Nursing-home Residents: A Post-hoc Analysis From A Large Cluster-randomized Trial.
Elie Saade, MD, MPH; Nina Joyce, PhD; Jessica Ogarek, MS; H. Edward Davidson, PharmD, MPH; Lisa Han, MPH; David Canaday, MD; Abul Yasin, MD; Theresa Shireman, PhD; Vincent Mor, PhD; Stefan Gravenstein, MD, MPH
Posters
  • Poster HDSD v10 -36x60_mm.pdf (827.1 kB)
  • A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants ≤3 Months of Age
    Jason Kim, MD, MSCE; Firdose Lambey Nakwa, MBBCh, FCPaeds, MMed Paeds; Fábio De Araujo Motta, MD, PhD; Perla Salcedo Lozada, MD; Derya Alabaz, MD; Hong Liu, MS; Keisha Bloise, MS; Mary Beth Dorr, PhD; Leah J. Anderson Gaffney, PhD; Nicholas Kartsonis, MD
    Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
    Tomas Mrkvan, PhD, MSc; Laura Campora, MD; Grégory Catteau, MSc; Martine Douha, MSc; Katrijn Grupping, PhD; Caroline Herve, PhD; George Kalema, PhD; Thomas Heineman, MD, PhD; Nicola P. Klein, MD, PhD; Himal Lal, MD; Lidia Oostvogels, MD; Anne Schuind, MD
    Pharmacist Prescribing and Care in Patients with Uncomplicated Urinary Tract Infections in the Community: Efficacy and Safety Outcomes of the RxOUTMAP Study
    Nathan Beahm, BSP, PharmD; Daniel Smyth, MD, FRCPC; Ross Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC, FCAHS
    Antiviral Effects, Pharmacokinetics (PK) and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants with Bronchiolitis, in the Phase 1b Study 53718678RSV1005
    Federico Martinon-Torres, MD, PhD, Assoc Prof; Sarah Rusch, MSc; Dymphy Huntjens, PhD; Bart Remmerie, Chem Eng; Johan Vingerhoets, PhD; Katie McFadyen, MPH; Fernando Ferrero, Md, PhD; Eugenio Baraldi, MD, FCCP; Pablo Rojo Conejo, MD, PhD; Cristina Epalza, MD; Marita Stevens, MD
    Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes in Patients Infected with Ceftriaxone Non-Susceptible, Extended Spectrum Beta-Lactamase and Multi-Drug Resistant Pathogens at Baseline
    Mohd Amin Mir, MS, MSc, PGDPM; Saransh Chaudhary, BSc (Hons); Kim Jacob Mammen, MCh (Urology); Rajeev Sood, MCh (Urology); P.N. Dogra, MCh (Urology); Sudhir Chadha, MCh (Urology); Ravimohan Mavuduru, MCh (Urology); Rahul Janak Sinha, MCh (Urology); Manu Chaudhary, PhD; Gazalla Shiekh, PhD
    Posters
  • 1959_PLEA_CT_MDR.pdf (1.8 MB)
  • Antibiotic Challenge Dose Testing Improves Patient Care and Lowers Costs in a Community Hospital: a Two-year Prospective Study
    Barbara Lambl, MD MPH; Samira Reyes-Dassum, MD; Vinit Oommen, MD; Oluchi Dike, MD; Monique Freeley, RPh; Darci Finocchiaro, MD; Japheth Mukaya, MD; AnaMaria Bensaci, MD MPH; Johanna O'Connor, MD; Kimberly G. Blumenthal, MD, MSc
    Posters
  • IDSA Poster FINAL 2018.pdf (3.2 MB)
  • A Randomized Controlled Trial of the Effect of Accelerated Copper Textiles on Healthcare-Associated Infections and Multidrug-Resistant Organisms: The “Investigating Microbial Pathogen Activity of Copper Textiles” (IMPACT) Study
    Ebbing Lautenbach, MD, MPH, MSCE, FIDSA, FSHEA; David Pegues, MD, FIDSA, FSHEA; Barry Fuchs, MD; Niels Martin, MD; Irving Nachamkin, DrPH, MPH; Warren Bilker, PhD; Pam Tolomeo, MPH; Leigh Cressman, MA; Jacqueline Omorgobe, BS; Kristen Johnson, BS; Jennifer Han, MD, MSCE
    TRAIL level and ImmunoXpert™ score complement molecular viral detection in the classification of febrile children – an interim analysis from the AutoPilotDx-study
    Tobias Tenenbaum, MD; Cihan Papan, MD; Marian Porwoll, Student; Ummaya Hakim, Medical Technician; Alberto Argentiero, MD; Ilaria Testa, MD; Maria Bruna Pasticci, MD; Daniele Mezzetti, MD; Katia Perruccio, MD; Liat Etshtein, MD; Niv Mastboim, BSc; Asi Cohen, PhD; Einav Simon, PhD; Olga Boico, PhD; Liran Shani, MD; Tanya Gottlieb, PhD; Roy Navon, MSc; Kfir Oved, PhD; Eran Eden, PhD; Arne Simon, MD; Johannes Liese, MD; Markus Knuf, MD; Sven Schneider, MD; Edoardo Farinelli, MD; Susanna Esposito, MD
    Microbiological Outcomes with Plazomicin (PLZ) versus Colistin (CST) in Patients (pts) with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE) in the CARE Study
    Alisa W. Serio, PhD; Alex Smith, MS; Kevin M. Krause, MBA; Irene Galani, PhD; Ana Cristina Gales, MD, PhD; Adrian Jubb, MBChB, PhD, FRCPath; Lynn E. Connolly, MD, PhD
    Posters
  • 1964_IDWeek Serio Poster_F.pdf (201.8 kB)
  • Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials
    Jurgen K Rockstroh, MD; Sanjay R Bhagani, MD; Chloe Orkin, MBBCh; Ruth Soto-Malave, MD; Karine Lacombe, MD, PhD; Zhenzhen Zhang, PhD; Stanley Wang, MD, PhD; Federico Mensa, MD; Roger Trinh, MD, MPH
    Procalcitonin-guided antibiotic therapy for lower respiratory tract infections in a US academic medical center
    Jennifer Townsend, MD; Victoria Adams-Sommer, PharmD; Panagis Galiatsatos, MD; David Pearse, MD; Flora Kisuule, MD; Hardin Pantle, MD; Mary Masterson, PA-C; Catherine Kiruthi, PharmD; Paul Ortiz, PharmD; Elsen Jacob, PharmD; Jacob Sama, MD; Michael Melgar, MD; Seema Nayak, MD; Jillian Irwin, MD; Cyrus Mazidi, MD; Sam Stern, MD; Albert Agbanlog, RN; Robert Jurao, RN; Kevin Psoter, PhD, MPA; Robin McKenzie, MD
    Posters
  • PCT Poster revised 9.2018.pdf (653.4 kB)
  • Comparison of Adverse Event Rates Between Patients Treated with Ceftaroline or Ceftriaxone
    Jeffrey W. Jansen, Pharm.D.; Travis W. Linneman, Pharm.D.; Xing Tan, Pharm.D.; Ryan P. Moenster, Pharm.D., FIDSA
    Phase 1 Clinical Trial of Intranasal Immunization with M2-deficient, Single Replication, Live Influenza Vaccine (M2SR): Safety and Immune Response in Adults
    Joseph Eiden, MD, PhD; Gilad Gordon, MD; Carlos Fierro, MD; Robert Belshe, MD; Harry Greenberg, MD, FIDSA; Dan Hoft, MD, PhD; Yasuko Hatta, DVM, PhD; Michael Imboden, PhD; Mike Moser, PhD; Renee Herber, BS; David Boltz, PhD; Magdalena Tary-Lehmann, MD, PhD; Yoshihiro Kawaoka, DVM, PhD; Gabriele Neumann, PhD; Paul Radspinner, MBA; Roger Aitchison, ScM; Pamuk Bilsel, PhD
    A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects
    Antonios Aliprantis, MD, PhD; Dennis Wolford, MS; Luzelena Caro, PhD; Brian Maas, PharmD; Hua Ma, PhD; Kalpit Vora, PhD; Dong Geng, PhD; Radha Railkar, PhD; Andrew Lee, MD; Laura Sterling, MD, MPH; Eseng Lai, MD, PhD
    Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared to PCV-13 in Healthy Older Adults Previously Vaccinated with 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
    Ulrike Buchwald, MD; James Peterson, MD; Helen Stacey, MD; Katie Julien, MD; Tina Sterling, BSN; Melanie Bruch, MD; Gretchen Tamms, BS; Jianing Li, PhD; Alison Pedley, PhD; Katrina Nolan, MD; Patrice Benner, MD; Chitrananda Abeygunawardana, MD; Michael Winters, PhD; Michael Kosinski, PhD; Jon Stek, BS; Luwy Musey, MD
    Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis
    Pankaj Mandale, MBBS, MPH; Mohd Amin Mir, MS, MSc, PGDPM; Saransh Chaudhary, BSc (Hons); Manu Chaudhary, PhD; Rajeev Sood, MCh (Urology); N. S Patil, MD (Microbiology); Salil Narang, MD (Pathology); Anurag Pyasi, PhD; Mohammad Shameem, MD, FRCP
    Posters
  • 1974_PLEA_CT_MIC.pdf (3.3 MB)
  • Time to Viral Suppression does not Impact SVR in Patients Treated with Glecaprevir/Pibrentasvir for 8 Weeks
    Christoph Sarrazin, MD; Tram Tran, MD; Douglas Dylla, Ph.D.; Jordan J. Feld, MD, MPH; Sanjeev Arora, MD; David Victor III, MD; Yiran B Hu, PhD; Stanley Wang, MD, PhD; Federico Mensa, MD; David L. Wyles, MD
    Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed Clostridium Difficile Infection (CDI)
    Samad Tirmizi, PharmD; Nadya Jammal, PharmD; Dayna McManus, PharmD, BCPS AQ-ID; Michael Ruggero, PharmD; Jeffrey Topal, MD
    Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry
    Jens Reimer, MD; Albrecht Stoehr, MD; Uwe Naumann, MD; Gerlinde Teuber, MD; Carsten Zamani, MD; Stefan Mauss, MD; Nazifa Qurishi, MD; Kristina Lohmann, PhD; Henning Kleine, PhD; Andreas Pangerl, MD; Stefan Christensen, MD
    Multiplex PCR-Based Analysis of Enteric Pathogens in Faecal Samples from Patients with Clostridium difficile Infection in the Randomised, Controlled EXTEND Study Comparing the Efficacy of Extended-Pulsed Fidaxomicin with Vancomycin Therapy
    Mark Wilcox, MD; Oliver A. Cornely, MD; Benoit Guery, MD; Christopher Longshaw, PhD; Areti Georgopali, MD; Andreas Karas, MD; Gbenga Kazeem, PhD; Jose Alejandro Palacios-Fabrega, PhD; Maria J. G. T. Vehreschild, MD
    Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of failed patients with assessment of MIC increases and changes in genotypic profile in PLEA (a Phase 3, Randomized, Double-blind Clinical Trial in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis)
    Mohd Amin Mir, MS, MSc, PGDPM; Saransh Chaudhary, BSc (Hons); Manu Chaudhary, PhD; Anurag Pyasi, PhD; N. S Patil, MD (Microbiology); Ruchi Girotra, DNB (Microbiology); Salil Narang, MD (Pathology); Nazish Fatima, MD (Microbiology)
    Posters
  • 1984_PLEA_CT_GENE.pdf (182.1 kB)
  • Atypical Symptoms and High Mortality Associated with Serogroup B Meningococcal Disease in Cartagena Colombia 2012-2016
    Wilfrido Coronell-Rodríguez, PhD Tropical Medicine, Infectious disease Pediatrician; Cindy Arteta-Acosta, Master of Epidemiology

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.